Crescent Biopharma is a clinical-stage biotechnology company developing cancer therapies through two main strategies: CR-001, a PD-1 x VEGF bispecific antibody designed as a potential immuno-oncology treatment to address the significant unmet need in patients who fail to respond adequately to checkpoint inhibitors, and a portfolio of antibody drug conjugates targeting different cancer indications. The company operates a partnership-driven revenue model, having established collaborations with Kelun Biotech (receiving upfront payments and milestone fees for exclusive rights to CR-003 outside Greater China and CR-001 within Greater China) and Paragon for its development programs, while contracting manufacturing with third-party biologics providers. Crescent is pre-commercial with no product revenue to date, and plans to commercialize approved products either through its own infrastructure or via external partnerships as therapies advance through clinical development.